{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:17:58Z","timestamp":1790983078758,"version":"4.1.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is an exceptionally rare glomerular disease, accounting for only 0.17\u20133.7% of all renal biopsies, and no consensus\u2013based treatment algo-rithm has been established. Although daratumumab, a humanized anti-CD38 monoclonal antibody, has shown promising efficacy in PGNMID, the existing evidence is limited to small case series using standard-dose regimens (16\u202fmg\/kg). Critically, data on reduced-dose daratumumab in elderly patients with CyBorD-refractory disease and multiple comorbidities remain scarce. This case report adds to the limited experience with a reduced-dose strategy in a high-risk elderly patient with CyBorD-refractory PGNMID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 73-year-old Chinese male with biopsy-proven PGNMID (IgG3-\n                      <jats:italic>\u03ba<\/jats:italic>\n                      subtype), chronic kidney disease stage 3a, a baseline serum creatinine 1.5\u202fmg\/dL (132.6\u202f\u03bcmol\/L), proteinuria 5.61\u202fg\/24\u202fh, and multiple comorbidities (hypertension, coronary artery disease, and prior cerebral infarction) received first-line CyBorD therapy (cyclophosphamide, bortezomib, and dexamethasone). After four cycles, he demonstrated treatment failure. He subsequently developed progressive renal deterioration [serum creatinine 2.7\u202fmg\/dL (239\u202f\u03bcmol\/L)], severe nephrotic-range proteinuria (10.61\u202fg\/24\u202fh), hypoalbuminemia (22.8\u202fg\/L), and decompensated heart failure. Given his advanced age and high infection risk, a risk-adapted regimen was administered monthly for 12\u202fcycles: reduced-dose daratumumab (400\u202fmg, \u223c6\u202fmg\/kg, 37.5% of the standard 16\u202fmg\/kg dose) combined with bortezomib 2.2\u202fmg. After 12\u202fmonths, the patient achieved partial renal remission: proteinuria decreased to 1.12\u202fg\/24\u202fh, serum albumin normalized to 38.1\u202fg\/L, serum creatinine stabilized at 1.6\u202fmg\/dL (141.4\u202f\u03bcmol\/L), immunofixation electrophoresis converted to negative, and clinical resolution of heart failure was achieved. Notably, no infectious complications were documented throughout the treatment period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case suggests that low-dose daratumumab combined with bortezomib may be a feasible and apparently well-tolerated salvage option in this selected patient with CyBorD-refractory PGNMID and a heavy comorbidity burden. The favourable outcome in this single case raises the possibility that dose de-escalation might preserve efficacy while mitigating toxicity, although this hypothesis requires confirmation in larger studies. This report adds to the limited global evidence for daratumumab in PGNMID and highlights the need for personalized, risk-stratified dosing strategies in this rare and challenging glomerulopathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1899020","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:23:04Z","timestamp":1786681384000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Low-dose daratumumab and bortezomib for the treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiaomei","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaying","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaomei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1523-1755.2004.00365.x","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis","volume":"65","author":"Nasr","year":"2004","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the international kidney and monoclonal gammopathy research group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e40978","DOI":"10.7759\/cureus.40978","article-title":"A comparative study of immunofluorescence on formalin-fixed, paraffin-embedded versus fresh frozen kidney biopsy","volume":"15","author":"Das","year":"2023","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/ndt\/gfz176","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective","volume":"36","author":"Bridoux","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1007\/s40620-022-01317-w","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: an entity associated with distinct diseases and comparison between IgG1 and IgG3 subtypes","volume":"35","author":"Liu","year":"2022","journal-title":"J Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","article-title":"How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.kint.2018.02.020","article-title":"A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"94","author":"Gumber","year":"2018","journal-title":"Kidney Int"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s11864-024-01273-6","article-title":"Acquired bortezomib resistance in multiple myeloma: from mechanisms to strategy","volume":"25","author":"Li","year":"2024","journal-title":"Curr Treat Options in Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1681\/ASN.2020101541","article-title":"Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits","volume":"32","author":"Zand","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.ekir.2021.05.008","article-title":"Daratumumab in patients with bortezomib-refractory proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"6","author":"Almaani","year":"2021","journal-title":"Kidney Int Rep"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.kint.2025.07.039","article-title":"Revisiting proliferative glomerulonephritis with monoclonal immunoglobulin deposits through immunoglobulin repertoire sequencing","volume":"108","author":"Javaugue","year":"2025","journal-title":"Kidney Int"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.ekir.2018.07.008","article-title":"Paraffin immunofluorescence: a valuable ancillary technique in renal pathology","volume":"3","author":"Nasr","year":"2018","journal-title":"Kidney Int Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000542497","article-title":"Immunofluorescence use and techniques in glomerular diseases: a review","volume":"4","author":"Messias","year":"2024","journal-title":"Glomerular Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ekir.2016.08.012","article-title":"Clinicopathologic features of membranous-like glomerulopathy with masked IgG kappa deposits","volume":"1","author":"Larsen","year":"2016","journal-title":"Kidney Int Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1360979","DOI":"10.3389\/fmed.2024.1360979","article-title":"Promising response of proliferative glomerulonephritis with monoclonal IgG deposits to low-dose daratumumab: a case report","volume":"11","author":"Xu","year":"2024","journal-title":"Front Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1899020\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:23:04Z","timestamp":1786681384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1899020\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":17,"alternative-id":["10.3389\/fmed.2026.1899020"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1899020","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1899020"}}